Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Aug 17, 2022
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex Pharmaceuticals Inc / Ma
| -3.75K |
$303.90 | -$1,138,722.73 | -28.06% | 9.61K | +1 |
Aug 15
|
Scheduled
| |||||
Vertex Pharmaceuticals Inc / Ma
| -36.00 |
$300.32 | -$10,811.52 | -0.27% | 13.35K | +1 |
Aug 10
|
Scheduled
| |||||
Vertex Pharmaceuticals Inc / Ma
| -946.00 |
$300.00 | -$283,800.00 | -6.60% | 13.39K | +1 |
Aug 9
|
Scheduled
| |||||
Vertex Pharmaceuticals Inc / Ma
| -133.00 |
$252.88 | -$33,633.06 | -0.92% | 14.33K | +1 |
May 16
|
Scheduled
| |||||
Vertex Pharmaceuticals Inc / Ma
| -120.00 |
$275.41 | -$33,048.88 | -0.83% | 14.33K | +1 |
Apr 29
|
Scheduled
| |||||
Vertex Pharmaceuticals Inc / Ma
| -1.55K |
$227.86 | -$354,094.44 | -9.71% | 14.45K | +1 |
Feb 24
| ||||||
Vertex Pharmaceuticals Inc / Ma
| -712.00 |
$232.51 | -$165,547.12 | -4.26% | 16.01K | +1 |
Feb 17
| ||||||
Vertex Pharmaceuticals Inc / Ma
| -474.00 |
$237.74 | -$112,688.76 | -2.76% | 16.72K | +1 |
Feb 10
| ||||||
Vertex Pharmaceuticals Inc / Ma
| 8.94K |
—
|
—
| +108.34% | 17.19K | +1 |
Feb 1
| ||||||
Vertex Pharmaceuticals Inc / Ma
| -112.00 |
$216.34 | -$24,230.11 | -1.34% | 8.25K | +1 |
May 17
|
Scheduled
| |||||
Vertex Pharmaceuticals Inc / Ma
| -5.14K |
$209.69 | -$1,078,017.59 | -38.38% | 8.25K | +1 |
Mar 5
|
Scheduled
| |||||
Vertex Pharmaceuticals Inc / Ma
|
0
|
—
|
—
|
—
|
0
| +1 | |||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||